Month: May 2025

Inflation Eases to 2.1% in April, Offering Potential Breathing Room to Fed

Posted on by slightbourne@noblecapitalmarkets.com
Key Points:
– April’s inflation rate slowed to 2.1%, lower than expected, easing pressure on the Federal Reserve.
– Consumer spending grew just 0.2%, while the savings rate jumped to 4.9%.
– Core PCE inflation held at 2.5% annually, supporting a wait-and-see approach from policymakers.

Inflation cooled in April, offering a potential signal that price pressures may be stabilizing and possibly giving the Federal Reserve more flexibility in managing interest rates. According to data released Friday by the Commerce Department, the personal consumption expenditures (PCE) price index — the Fed’s preferred inflation gauge — rose just 0.1% for the month, bringing the annual rate down to 2.1%. That figure is slightly below expectations and marks the lowest inflation reading of the year so far.

Core PCE, which strips out the more volatile food and energy categories and is considered a better indicator of long-term inflation trends, also increased just 0.1% in April. On a year-over-year basis, core inflation stood at 2.5%, slightly under the anticipated 2.6%.

These subdued inflation figures arrive amid a backdrop of softer consumer spending and a jump in personal savings. Consumer spending rose just 0.2% for the month — a sharp slowdown from the 0.7% gain in March. Meanwhile, the personal savings rate surged to 4.9%, its highest level in nearly a year. This suggests that households may be pulling back on discretionary purchases and becoming more cautious with their finances.

The moderation in price increases could provide the Federal Reserve with more breathing room as it considers the trajectory of interest rates. While the Fed has resisted calls for rate cuts amid lingering inflation concerns, a sustained easing trend could support a policy shift later this year. However, the central bank remains wary, particularly as some inflationary risks — such as potential tariff impacts — loom in the background.

Energy prices ticked up by 0.5% in April, while food prices dipped by 0.3%. Shelter costs, a key driver of persistent inflation in recent months, continued to rise at a 0.4% pace. Nonetheless, the overall inflation picture showed clear signs of deceleration.

Notably, personal income climbed by 0.8% in April, well above the 0.3% estimate. This growth in income, paired with higher savings, points to a consumer base that may be more financially resilient than previously thought, even if spending has temporarily cooled.

Markets responded with relative indifference to the inflation data. Stock futures drifted lower and Treasury yields were mixed, as investors weighed the implications for future monetary policy against broader economic uncertainties.

Recent trade tensions — especially President Trump’s imposition of sweeping tariffs and the ongoing legal back-and-forth over their legitimacy — add complexity to the outlook. While the direct inflationary impact of tariffs has so far been muted, economists warn that higher input costs could feed into prices later this year if tariff policies persist.

Looking ahead, the Fed will be closely monitoring inflation trends, consumer behavior, and labor market developments. If price pressures remain tame and growth conditions warrant, the central bank may eventually consider adjusting rates — though for now, caution remains the guiding principle.

Release – Snail Inc.’s Independent Label, Wandering Wizard, Expands Global Market Presence Through Publishing Partnership with LATAM Studio Seven Leaf Clover

Posted on by aweinsoff@channelchek.com

Research News and Market Data on SNAL

May 30, 2025 at 8:30 AM EDT

PDF Version

CULVER CITY, Calif., May 30, 2025 (GLOBE NEWSWIRE) — Snail, Inc. (Nasdaq: SNAL) (“Snail Games” or the “Company”), a leading global independent developer and publisher of interactive digital entertainment, announced that its independent indie publishing label, Wandering Wizard, entered into a publishing partnership with Argentina-based developer Seven Leaf Clover, to acquire the publishing rights to Rebel Engine, a high-impact, single-player, first-person shooter (“FPS”) game. Expected to release on PC in 2025, the Company expects that Rebel Engine will further expand Wandering Wizard’s footprint in the global gaming market.

Rebel Engine is a fast-paced FPS action game that blends visceral melee combat with powerful gunplay and a fluid, combo-driven system. Set in a stylized robot dystopia, players assume the role of Asimov, an enslaved machine who escapes corporate control and leads a revolution against a megacorporation. The game offers multiple melee weapon styles, custom combos, intense boss fights, and a narrative that explores themes of identity, resistance, and liberation.

Snail, Inc.’s Co-Chief Executive Officer, Tony Tian, commented: “The addition of Rebel Engine to Wandering Wizard’s expanding portfolio reinforces Snail’s broader mission to build a diversified and resilient gaming lineup and expand our reach into the global gaming market. We’re honored to partner with Seven Leaf Cover and look forward to supporting Rebel Engine through its launch later this year.”

Wandering Wizard and Seven Leaf Clover aim to showcase the creative and commercial potential of cross-regional collaboration with Rebel Engine, reinforcing Snail’s long-term strategy of cultivating diverse talent and delivering premium indie experiences on a global scale.

For creators interested in collaborative opportunities reach out at creatordirect@noiz.gg

Wishlist Rebel Engine on Steam https://store.steampowered.com/app/1977200/Rebel_Engine/

Rebel Engine Press Kit

About Seven Leaf Clover
Seven Leaf Clover is an independent team from Argentina committed to pushing the boundaries of game design. With rebellion as a core pillar, the studio creates intense and meaningful experiences that challenge industry standards, both thematically and mechanically. Their work delves into unconventional narratives and mechanics as a vehicle to question norms and forge new, uncharted paths in video games.

About Wandering Wizard
Wandering Wizard is passionately committed to championing indie game developers. We provide a platform for fresh voices, revolutionary ideas, and daring experiments within the indie gaming realm. Embracing the inherent risks of indie game development, we partner with creators worldwide to enrich the global gaming community with inclusive, inspiring, and innovative gaming experiences.

About Snail, Inc.
Snail, Inc. (Nasdaq: SNAL) is a leading, global independent developer and publisher of interactive digital entertainment for consumers around the world, with a premier portfolio of premium games designed for use on a variety of platforms, including consoles, PCs, and mobile devices. For more information, please visit: https://snail.com/.

Forward-Looking Statements

This press release contains statements that constitute forward-looking statements. Many of the forward-looking statements contained in this press release can be identified by the use of forward-looking words such as “anticipate,” “believe,” “could,” “expect,” “should,” “plan,” “intend,” “may,” “predict,” “continue,” “estimate” and “potential,” or the negative of these terms or other similar expressions. Forward-looking statements appear in a number of places in this press release and include, but are not limited to, statements regarding Rebel Engine’s potential to further expand Wandering Wizard’s footprint and reach in the global gaming market, thereby reinforcing Snail’s long-term strategy of cultivating diverse talent and delivering premium indie experiences on a global scale. You should carefully consider the risks and uncertainties described in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which was filed by the Company with the SEC on March 26, 2025 and other documents filed by the Company from time to time with the SEC, including the Company’s Forms 10-Q filed with the SEC. The Company does not undertake or accept any obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.

Investor Contact:
John Yi and Steven Shinmachi
Gateway Group, Inc.
949-574-3860
SNAL@gateway-grp.com

Release – Bitcoin Depot Eliminates Up-C Corporate Structure

Posted on by aweinsoff@channelchek.com

Research News and Market Data on BTM

May 30, 2025 8:00 AM EDT Download as PDF

Simplified Corporate Structure Reduces Compliance and Reporting Complexity, Lowers Cash Tax Burden

ATLANTA, May 30, 2025 (GLOBE NEWSWIRE) — Bitcoin Depot Inc. (Nasdaq: BTM) (“Bitcoin Depot” or the “Company”), a U.S.-based Bitcoin ATM operator and leading fintech company, announced it has simplified its organizational and capital structure by eliminating its Up-C Restructuring (the “Up-C Restructuring”).

Pursuant to the Up-C Restructuring, BT Assets, Inc., an entity controlled by the Company’s Founder and CEO, Brandon Mintz, that held Common Units in BT HoldCo LLC and shares of the Company’s Class V Common Stock has merged with a subsidiary of the Company and received 41,193,024 shares of the Company’s Class M common stock, which will continue to carry 10 votes per share, as consideration in the merger.

In connection with the Up-C Restructuring, all of the shares of the Company’s Class V Common Stock held by BT Assets have been transferred to the Company and cancelled. After giving effect to the Up-C Restructuring, Mintz holds a total of 41,193,024 shares of the Company’s Class M Common Stock and 142,973 shares of the Company’s Class A Common Stock.

Post-transaction, Bitcoin Depot now wholly-owns its principal operating subsidiaries. The Company believes the simpler structure will offer benefits like better stock liquidity, easier use of stock for acquisitions, and a clearer corporate profile.

In addition, the Up-C Restructuring extinguishes the $2.2 million Tax Receivable Agreement liability and will lead to further long-term savings, as the Company estimates its cash tax rate will be reduced by an estimated 12 percentage points. Other professional services costs associated with tax, accounting and legal will also be reduced by this simpler structure.

About Bitcoin Depot

Bitcoin Depot Inc. (Nasdaq: BTM) was founded in 2016 with the mission to connect those who prefer to use cash to the broader, digital financial system. Bitcoin Depot provides its users with simple, efficient and intuitive means of converting cash into Bitcoin, which users can deploy in the payments, spending and investing space. Users can convert cash to bitcoin at Bitcoin Depot kiosks in 48 states and at thousands of name-brand retail locations in 29 states through its BDCheckout product. The Company has the largest market share in North America with over 8,400 kiosk locations as of February 25, 2025.  Learn more at www.bitcoindepot.com. 

Cautionary Statement Regarding Forward-Looking Statements

This press release and any oral statements made in connection herewith include “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Exchange Act of 1934, as amended. Forward-looking statements are any statements other than statements of historical fact, and include, but are not limited to, statements regarding the expectations of plans, business strategies, objectives and growth and anticipated financial and operational performance, including our growth strategy and ability to increase deployment of our products and services, our ability to strengthen our financial profile, and worldwide growth in the adoption and use of cryptocurrencies. These forward-looking statements are based on management’s current beliefs, based on currently available information, as to the outcome and timing of future events. Forward-looking statements are often identified by words such as “anticipate,” “appears,” “approximately,” “believe,” “continue,” “could,” “designed,” “effect,” “estimate,” “evaluate,” “expect,” “forecast,” “goal,” “initiative,” “intend,” “may,” “objective,” “outlook,“ ”plan,“ ”potential,“ ”priorities,“ ”project,“ ”pursue,“ ”seek,“ ”should,“ ”target,“ ”when,“ ”will,“ ”would,” or the negative of any of those words or similar expressions that predict or indicate future events or trends or that are not statements of historical matters, although not all forward-looking statements contain such identifying words. In making these statements, we rely upon assumptions and analysis based on our experience and perception of historical trends, current conditions, and expected future developments, as well as other factors we consider appropriate under the circumstances. We believe these judgments are reasonable, but these statements are not guarantees of any future events or financial results. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond our control.

These forward-looking statements are subject to a number of risks and uncertainties, including changes in domestic and foreign business, market, financial, political and legal conditions; failure to realize the anticipated benefits of the business combination; risks relating to the uncertainty of our projected financial information; future global, regional or local economic and market conditions; the development, effects and enforcement of laws and regulations; our ability to manage future growth; our ability to develop new products and services, bring them to market in a timely manner and make enhancements to our platform; the effects of competition on our future business; our ability to issue equity or equity-linked securities; the outcome of any potential litigation, government and regulatory proceedings, investigations and inquiries; and those factors described or referenced in filings with the Securities and Exchange Commission. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that we do not presently know or that we currently believe are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect our expectations, plans or forecasts of future events and views as of the date of this press release. We anticipate that subsequent events and developments will cause our assessments to change.

We caution readers not to place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date they are made, and we undertake no obligation to update publicly or otherwise revise any forward-looking statements, whether as a result of new information, future events, or other factors that affect the subject of these statements, except where we are expressly required to do so by law. All written and oral forward-looking statements attributable to us are expressly qualified in their entirety by this cautionary statement.

Contacts:

Investors 
Cody Slach,
Gateway Group, Inc. 
949-574-3860 
BTM@gateway-grp.com

Media 
Brenlyn Motlagh, Ryan Deloney 
Gateway Group, Inc.
949-574-3860 
BTM@gateway-grp.com

Primary Logo

Source: Bitcoin Depot Inc.

Released May 30, 2025

Conduent (CNDT) – DOGE Concerns Offer Attractive Investment Opportunity

Posted on by slightbourne@noblecapitalmarkets.com


Friday, May 30, 2025

Patrick McCann, CFA, Research Analyst, Noble Capital Markets, Inc.

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Investment thesis on track. We believe the company is on track to deliver on our full-year revenue and adj. EBITDA forecast, despite investor concerns around federal budget cuts, to which we believe the company has limited actual exposure. Moreover, although there may be some concerns over disruption from potential new asset sales, we anticipate that additional sales would likely focus on lower-margin business units and could help to bolster the company’s long-term cashflow margin profile.

Re-affirming full year 2025 estimates. While we are largely maintaining our full year estimates, we are fine-tuning the quarterly cadence of adj. EBITDA to better reflect seasonality. Our Q2 and Q3 adj. EBITDA estimates are raised to $33 million and $52 million, respectively, while Q4 is lowered to $54 million, reflecting factors tied to SNAP and Medicare enrollment. We expect 2026 revenue growth of 3% to $3.22 billion with adj. EBITDA margin expansion to 8.0%.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Xcel Brands (XELB) – Building A Sizeable Social Media Presence

Posted on by slightbourne@noblecapitalmarkets.com


Friday, May 30, 2025

Xcel Brands, Inc. 1333 Broadway 10th Floor New York, NY 10018 United States https:/Sector(s): Consumer Cyclical Industry: Apparel Manufacturing Full Time Employees: 84 Key Executives Name Title Pay Exercised Year Born Mr. Robert W. D’Loren Chairman, Pres & CEO 1.27M N/A 1958 Mr. James F. Haran CFO, Principal Financial & Accou

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Jacob Mutchler, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Lackluster Q4 results. The company reported Q4 revenue of $1.2 million and an adj. EBITDA loss of $0.8 million, both of which were well below our estimates of $2.6 million and $0.2 million, respectively, as illustrated in Figure #1 Q4 Results. Notably, while Q4 results were softer than expected, the company has signed several new brands this year, which have yet to impact operating results. Importantly, the new brand launches have increased the company’s total social media following from 5 million to 45 million over the past five months, a significant step towards reaching its goal of 100 million followers.

Preliminary Q1 results. Additionally, the company provided preliminary Q1 results of $1.33 million in revenue, a decrease from $2.18 million last year, and an expected net loss of roughly $2.67 million, which is an improvement from a net loss of $6.35 million last year. The improvement in net loss is attributable to a $0.8 million improvement in core operating results and a $2.3 million impairment charge recorded in the prior year period. 


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

E.l.f. Beauty Bets Big on Skincare, Acquires Hailey Bieber’s Rhode for $1 Billion

Posted on by slightbourne@noblecapitalmarkets.com
Key Points:
– E.l.f. acquires Hailey Bieber’s Rhode to expand into high-end skincare.
– Rhode hit $212M in sales in 3 years, driven by DTC and social media.
– Rhode to launch in Sephora; Bieber stays on as creative head.

E.l.f. Beauty is making a bold move into the luxury skincare space with its acquisition of Hailey Bieber’s skincare brand, Rhode, in a deal valued at up to $1 billion. The acquisition, announced Wednesday, marks E.l.f.’s largest to date and signals a strategic shift to broaden its appeal and strengthen its skincare portfolio.

The deal includes $800 million in cash and stock, with an additional $200 million contingent on Rhode’s performance over the next three years. It’s expected to close later this year, during the second quarter of E.l.f.’s fiscal 2026.

Founded in 2022 by Bieber and co-founders Michael and Lauren Ratner, Rhode has skyrocketed to success in just three years, generating $212 million in net sales with a minimalist product lineup. The brand’s direct-to-consumer model and social media dominance — particularly on TikTok — have driven exponential growth and massive brand awareness.

“I’ve been in the consumer space for 34 years, and I’ve never seen anything like this,” said E.l.f. CEO Tarang Amin. “Rhode disrupted the skincare market with just 10 products and a clear, authentic voice.”

Hailey Bieber will stay on as Rhode’s Chief Creative Officer and Head of Innovation, continuing to oversee marketing and product development. In a statement, she expressed excitement about scaling Rhode with E.l.f., saying the partnership will “elevate and accelerate” their reach and global distribution.

While Rhode has operated exclusively through its website, it is set to launch in Sephora stores across North America and the U.K. before year-end — a move expected to significantly boost retail presence and revenue.

Goldman Sachs analysts called the acquisition a “strategic positive,” praising Rhode’s potential to elevate E.l.f.’s brand value and attract a higher-income customer segment. Rhode’s average product price — in the high $20 range — complements E.l.f.’s affordable core products, which start around $6.50.

This move follows E.l.f.’s 2023 acquisition of Naturium for $355 million, underscoring its commitment to expanding in skincare — a category with growing demand among younger consumers.

However, the timing poses challenges. E.l.f. is funding $600 million of the deal with debt amid high interest rates, and it faces uncertainty around tariffs on Chinese imports, from which it sources 75% of its products. The company is also planning a $1 price hike beginning in August to counter rising costs.

Despite these headwinds, E.l.f. reported strong Q4 results: earnings per share of $0.78 (vs. $0.72 expected) and $333 million in revenue (vs. $328 million forecasted). But due to ongoing trade tensions and tariff risks, the company declined to offer guidance for fiscal 2026.

The Rhode deal reflects E.l.f.’s confidence in premium skincare’s resilience—even in a shaky economic climate—and positions the brand to capture a larger share of the beauty market with innovative, high-impact products.

Zeo Energy to Acquire Heliogen, Forming a Comprehensive Clean Energy Platform

Posted on by slightbourne@noblecapitalmarkets.com
Key Points:
– Zeo to acquire Heliogen in an all-stock deal, expanding its clean energy reach.
– Adds long-duration storage, targeting sectors like data centers and AI.
– Boosts efficiency and financing for large-scale energy projects.

In a move that underscores the accelerating convergence of solar energy and long-duration storage solutions, Zeo Energy Corp. (Nasdaq: ZEO) has announced its acquisition of Heliogen, Inc. (OTCQX: HLGN) in an all-stock transaction valued at approximately $10 million. The deal aims to create a unified clean energy platform that serves residential, commercial, and utility-scale markets across the U.S. and beyond.

Zeo Energy, a Florida-based provider of residential solar and energy efficiency services, will integrate Heliogen’s advanced storage technologies to expand into commercial and industrial-scale clean energy applications. These include mission-critical sectors such as data centers, AI infrastructure, and cloud computing facilities—markets increasingly in need of reliable, scalable, and cost-effective energy solutions.

The acquisition represents the outcome of Heliogen’s comprehensive strategic alternatives review and is expected to close in the third quarter of 2025, pending regulatory and shareholder approvals. With the deal’s completion, Heliogen’s shareholders will receive Zeo Class A common stock and the combined entity will retain key technical personnel to drive innovation across new market segments.

This transaction marks a strategic pivot for Zeo, positioning it as a more vertically integrated energy provider with diversified revenue streams and operational reach. The company expects to streamline corporate overhead, broaden its market appeal, and strengthen its balance sheet with the addition of Heliogen’s intellectual property and cash reserves.

Zeo also plans to leverage its affiliated financing arm—responsible for over $44 million in clean energy tax equity financing to date—to support future utility-scale and long-duration projects. This added financing capacity may be particularly beneficial as demand surges for low-carbon infrastructure driven by policy incentives, energy cost volatility, and technological adoption.

For investors, the combined company represents a multi-faceted play on the growing shift toward decarbonization and distributed energy. While Zeo brings an established presence in high-growth residential markets, Heliogen offers utility-grade thermal storage and dispatchable energy systems that address one of the most critical gaps in the clean energy transition: 24/7 reliability.

Both boards have unanimously approved the transaction, and early support from a significant portion of Heliogen’s shareholders has added momentum to the closing process. Once finalized, the deal is expected to create a scalable clean energy company well-positioned to meet rising demand across a broad spectrum of energy users.

As the energy landscape continues to evolve, the Zeo–Heliogen merger reflects a broader industry trend toward integrated platforms capable of delivering end-to-end clean energy solutions—from rooftop solar panels to large-scale grid storage.

Release – Details of Annual & Special Meeting of Aurania Shareholders

Posted on by aweinsoff@channelchek.com

Research News and Market Data on AUIAF

May 29, 2025 5:10 PM EDT | Source: Aurania Resources Ltd.

Toronto, Ontario–(Newsfile Corp. – May 29, 2025) – Aurania Resources Ltd. (TSXV: ARU) (OTCQB: AUIAF) (FSE: 20Q) (“Aurania” or the “Company”) announces that its Annual and Special Meeting of Shareholders (the “Meeting”) will be held at 1:30pm ET on Thursday, June 12, 2025, at the Company’s offices at 8 King Street East, Suite 1800, Toronto, ON M5C 1B5.

Aurania’s President & CEO, Dr. Keith Barron, is planning to provide a brief update on activities following the formal part of the Meeting. The Company expects to provide a link to a video and/or audio replay of Dr. Barron’s update sometime following the Meeting.

Proxy Voting Deadline
To ensure your vote is counted, please cast your vote prior to Tuesday, June 10th, 2025, at 1:30pm ET as per the details in your form of proxy. Meeting materials can be found on Aurania’s website under the Annual General Meeting tab.

Financial Statements and MD&A (Management’s Discussion & Analysis)
Aurania’s interim financial statements and MD&A for three months ended March 31, 2025, are available on SEDAR+ and the Company’s website.

About Aurania
Aurania is a mineral exploration company engaged in the identification, evaluation, acquisition, and exploration of mineral property interests, with a focus on precious metals and copper in South America. Its flagship asset, The Lost Cities – Cutucu Project, is located in the Jurassic Metallogenic Belt in the eastern foothills of the Andes mountain range of southeastern Ecuador.

Information on Aurania and technical reports are available at www.aurania.com and www.sedarplus.ca, as well as on Facebook at https://www.facebook.com/auranialtd/, Twitter at https://twitter.com/auranialtd, and LinkedIn at https://www.linkedin.com/company/aurania-resources-ltd.

For further information, please contact:

Carolyn Muir
VP Corporate Development & Investor Relations
Aurania Resources Ltd.
(416) 367-3200
carolyn.muir@aurania.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

info

SOURCE: Aurania Resources Ltd.

Release – GeoVax Congratulates Bipartisan Senate Action to Onshore Critical Medical Manufacturing

Posted on by aweinsoff@channelchek.com

Research News and Market Data on GOVX

Highlights Broad National Support for Domestic Vaccine Resilience and Role of MVA Platform in Public Health Preparedness

ATLANTA, GA – May 29, 2025 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies, voiced strong support for the newly announced bipartisan initiative by U.S. Senators Joni Ernst (R-IA) and Lisa Blunt Rochester (D-DE) to onshore the manufacturing of critical pharmaceutical supplies. The Critical Infrastructure Manufacturing Feasibility Act seeks to reduce reliance on foreign sources for key medical products—directly aligning with GeoVax’s mission to rebuild U.S.-based vaccine manufacturing and strengthen national preparedness.

“We are seeing a unified, national groundswell—from Congress, the White House, HHS, FDA, BARDA, and commissions like NSCEB—calling for the onshoring of America’s vaccine manufacturing base,” said David Dodd, Chairman and CEO of GeoVax. “GeoVax is purpose-built to answer that call, with a clinically validated MVA platform, a domestic manufacturing strategy, and a focus on pandemic responsiveness and protection of the immunocompromised.”

Rebuilding U.S. Biomanufacturing Through Coordinated Federal Action

The Senate initiative complements a cascade of government actions to bring the manufacturing of essential medical countermeasures—including vaccines—back to U.S. soil including:

  • The White House Executive Order on pharmaceutical independence.
  • The HHS-ASPR-DARPA EQUIP-A-Pharma initiative.
  • BARDA’s Rapid Response Partnership Vehicle (RRPV), which selected GeoVax’s MVA manufacturing proposal for award (pending funding).
  • The NSCEB’s call for $15 billion in U.S.-owned biotech infrastructure.

These actions reflect growing bipartisan recognition that national health security depends on resilient, scalable domestic vaccine capacity.

MVA Technology: Protecting the Immunocompromised with Durable, Multi-Antigen Vaccines

GeoVax’s MVA platform supports a pipeline of multi-antigen vaccines, including GEO-CM04S1 (COVID-19), primarily targeted to address the current unmet needs inducing broad T-cell and antibody responses among immunocompromised individuals, overcoming the limitations of single-antigen vaccines.

GeoVax’s MVA vaccines align with FDA and HHS goals to advance diversified, multi-antigenic strategies that provide broader, longer-lasting protection across high-risk groups.

Enabling U.S. Biomanufacturing Through Equip-A and BARDA RRPV: A Roadmap to Rapid, U.S.-Based Vaccine Production

GeoVax’s progressing advanced MVA manufacturing process is anticipated to eliminate the need for pathogen-free eggs and leverage a continuous avian cell line system, directly supporting the objectives of the federal government’s EQUIP-A-Pharma initiative. This HHS-ASPR-DARPA program aims to create agile, point-of-care pharmaceutical production capabilities using modular, AI-driven platforms.

Additionally, GeoVax’s proposal—“Innovation in Clinical Manufacturing of MVA-Vectored COVID-19 Vaccines”—was selected by BARDA’s Rapid Response Partnership Vehicle (RRPV), pending funding availability. The program is designed to accelerate the scale-up of advanced U.S.-based MVA vaccine manufacturing. The proposal is designed to:

  • Replace legacy egg-based systems with a continuous avian cell line (AGE1);
  • Enable high-volume, GMP-compliant vaccine output deployable within months—not years;
  • Support rapid pandemic response and reduce foreign supply chain dependencies;
  • Lay the foundation for broader applications across multiple infectious disease targets.

If funded, this effort is expected to create a scalable, resilient domestic manufacturing platform essential for the rapid deployment of MVA-based vaccines like GEO-CM04S1 (COVID-19) and GEO-MVA (Mpox/smallpox).

Platform Alignment with National Priorities

GeoVax’s MVA-based vaccines embody the shift in U.S. public health strategy away from single-antigen platforms and toward multi-antigen, durable, and safe alternatives. These vaccines are specifically engineered to meet the needs of high-risk populations—including the 40+ million immunocompromised Americans who may not respond effectively to mRNA and other vaccines that focus primarily on inducing antibody immunity.

GeoVax’s U.S.-controlled MVA platform addresses key government objectives:

  • Vaccine arsenal diversification (beyond mRNA and other single-antigen platforms)
  • Domestic manufacturing readiness
  • Transparency and public trust
  • Simplified global access and affordability
  • National security through supply chain independence
  • Products ready for rapid clinical and regulatory advancement
  • Vaccines built for strategic stockpiling and broad immunization

Call for Continued Bipartisan Momentum

“With renewed bipartisan focus on U.S. medical independence, there is no better time to invest in American-homegrown vaccine innovation,” added Dodd. “We urge lawmakers and federal agencies to continue supporting domestic capacity, biodefense readiness, and equitable access to advanced medical countermeasures to protect both our national security and our most vulnerable populations.”

About GeoVax

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines against infectious diseases and therapies for solid tumor cancers. The Company’s lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. The Company is also developing GEO-MVA, a vaccine targeting Mpox and smallpox. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. For more information about the current status of our clinical trials and other updates, visit our website: www.geovax.com.

Forward-Looking Statements

This release contains forward-looking statements regarding GeoVax’s business plans. The words “believe,” “look forward to,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax is able to obtain acceptable results from ongoing or future clinical trials of its investigational products, GeoVax’s immuno-oncology products and preventative vaccines can provoke the desired responses, and those products or vaccines can be used effectively, GeoVax’s viral vector technology adequately amplifies immune responses to cancer antigens, GeoVax can develop and manufacture its immuno-oncology products and preventative vaccines with the desired characteristics in a timely manner, GeoVax’s immuno-oncology products and preventative vaccines will be safe for human use, GeoVax’s vaccines will effectively prevent targeted infections in humans, GeoVax’s immuno-oncology products and preventative vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete development, there is development of competitive products that may be more effective or easier to use than GeoVax’s products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control.

Further information on our risk factors is contained in our periodic reports on Form 10-Q and Form 10-K that we have filed and will file with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law. 

Company Contact:                 

info@geovax.com                   

678-384-7220                          

Investor Relations Contact:

geovax@precisionaq.com

212-698-8696

Release – Euroseas Ltd. Announces Agreement to Sell its 2005-built 6,350 teu Intermediate Containership, M/V Marcos V

Posted on by aweinsoff@channelchek.com

Research News and Market Data on ESEA

May 29, 2025 09:15 ET

ATHENS, Greece, May 29, 2025 (GLOBE NEWSWIRE) — Euroseas Ltd. (NASDAQ: ESEA, the “Company” or “Euroseas”), an owner and operator of container carrier vessels and provider of seaborne transportation for containerized cargoes, announced today that it has signed an agreement to sell M/V Marcos V, an 6,350 teu intermediate containership built in 2005, to an unaffiliated third party, for $50 million. The vessel is scheduled to be delivered to its buyer in October 2025. The Company is expected to recognize a gain on the sale in excess of $8.50 million, or $1.20 per share.

Aristides Pittas, Chairman and CEO of Euroseas commented: “We are pleased to announce our agreement to sell our M/V Marcos V for a total price consideration of $50 million. The vessel was acquired in Q4 2021 for $40m, attached with a time charter contract at a rate of $42,000 per day for three years, plus a fourth year at the option of the charterer at $15,000 per day which was exercised. M/V Marcos V, upon its delivery to its new owners in October 2025, will have generated exceptional returns to our shareholders, realizing more than five times our original equity investment.”

Fleet Profile:
The Euroseas Ltd. fleet profile is currently as follows:

NameTypeDwtTEUYear BuiltEmployment (*)TCE Rate ($/day)
       
Container Carriers      
MARCOS V(+)(***)Intermediate72,9686,3502005TC until Oct-25$15,000
SYNERGY BUSAN(*)Intermediate50,7264,2532009TC until Dec-27$35,500
SYNERGY ANTWERP(*)Intermediate50,7264,2532008TC until May-28$35,500
SYNERGY OAKLAND(*)Intermediate50,7874,2532009TC until May-26$42,000
SYNERGY KEELUNG(+)(*)Intermediate50,9694,2532009TC until Jun-25
then until Jun-28		$23,000
$35,500
EMMANUEL P(+)Intermediate50,7964,2502005TC until Aug-25$21,000
RENA P(+)Intermediate50,7964,2502007TC until Aug-25
then until Aug-28		$21,000
$35,500
EM KEA(*)Feeder42,1653,1002007TC until May-26$19,000
GREGOS(*)Feeder37,2372,8002023TC until Apr-26$48,000
TERATAKI(*)Feeder37,2372,8002023TC until Jul-26$48,000
TENDER SOUL(*)Feeder37,2372,8002024TC until Oct-27$32,000
LEONIDAS Z(*)Feeder37,2372,8002024TC until Mar-26$20,000
DEAR PANELFeeder37,2372,8002025TC until Nov-27$32,000
SYMEON PFeeder37,2372,8002025TC until Nov-27$32,000
EVRIDIKI G(*)Feeder34,6772,5562001TC until Apr-26$29,500
EM CORFU(*)Feeder34,6542,5562001TC until Aug-26$28,000
STEPHANIA K(*)Feeder22,2621,8002024TC until May-26$22,000
MONICA(*)Feeder22,2621,8002024TC until May-27$23,500
PEPI STAR(*)Feeder22,2621,8002024TC until Jun-26$24,250
EM SPETSES(*)Feeder23,2241,7402007TC until Feb-26$18,100
JONATHAN P(*)Feeder23,3571,7402006TC until Sep-25$20,000
EM HYDRA(*)Feeder23,3511,7402005TC until May-27$19,000
       
Total Container Carriers on the Water22849,40467,494   
       
Vessels under constructionTypeDwtTEUTo be deliveredEmploymentTCE Rate ($/day)
ELENA (H1711)Intermediate55,2004,300Q4 2027  
NIKITAS G (H1712)Intermediate55,2004,300Q4 2027  
Total under construction2110,4008,600   
       

Notes:  

(*)TC denotes time charter. Charter duration indicates the earliest redelivery date; all dates listed are the earliest redelivery dates under each TC unless the contract rate is lower than the current market rate in which cases the latest redelivery date is assumed; vessels with the latest redelivery date shown are marked by (+).
(**) Rate is net of commissions (which are typically 5-6.25%)
(***) The vessel is sold and is expected to be delivered to its new owners in the fourth quarter of 2025

About Euroseas Ltd.

Euroseas Ltd. was formed on May 5, 2005 under the laws of the Republic of the Marshall Islands to consolidate the ship owning interests of the Pittas family of Athens, Greece, which has been in the shipping business over the past 140 years. Euroseas trades on the NASDAQ Capital Market under the ticker ESEA. 

Euroseas operates in the container shipping market. Euroseas’ operations are managed by Eurobulk Ltd., an ISO 9001:2008 and ISO 14001:2004 certified affiliated ship management company, which is responsible for the day-to-day commercial and technical management and operations of the vessels. Euroseas employs its vessels on spot and period charters and through pool arrangements. 

The Company has a fleet of 22 vessels, including 15 Feeder containerships and 7 Intermediate containerships with a cargo capacity of 67,494 teu. After the sale of M/V Marcos V and the delivery of the two intermediate containership newbuildings in 2027, Euroseas’ fleet will consist of 23 vessels with a total carrying capacity of 69,744 teu.

Forward Looking Statement

This press release contains forward-looking statements (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) concerning future events and the Company’s growth strategy and measures to implement such strategy; including expected vessel acquisitions and entering into further time charters. Words such as “expects,” “intends,” “plans,” “believes,” “anticipates,” “hopes,” “estimates,” and variations of such words and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates that are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of the Company. Actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to changes in the demand for containerships, competitive factors in the market in which the Company operates; risks associated with operations outside the United States; and other factors listed from time to time in the Company’s filings with the Securities and Exchange Commission. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. 

Visit our website www.euroseas.gr

Company ContactInvestor Relations / Financial Media
Tasos Aslidis
Chief Financial Officer
Euroseas Ltd.
11 Canterbury Lane,
Watchung, NJ 07069
Tel. (908) 301-9091
E-mail: aha@euroseas.gr		Nicolas Bornozis
Markella Kara
Capital Link, Inc.
230 Park Avenue, Suite 1540
New York, NY 10169
Tel. (212) 661-7566
E-mail: euroseas@capitallink.com

Release – Cocrystal Pharma’s Investigational Drug Candidate CC-42344 Demonstrates Strong Antiviral Potency Against the 2024 Highly Pathogenic H5N1 Avian Influenza Strain

Posted on by aweinsoff@channelchek.com

Research News and Market Data on COCP

May 29, 2025

 Download as PDF

  • CC-42344 was shown to be highly active against the highly pathogenic 2024 Texas H5N1 avian influenza strain
  • The Company’s virology study further confirmed the previous structural and in vitro data that revealed the binding of CC-42344 to PB2 protein of the 2024 H5N1 avian influenza virus

BOTHELL, Wash., May 29, 2025 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that a recent virology study showed its novel, broad-spectrum influenza PB2 inhibitor CC-42344 exhibits strong antiviral activity against the highly pathogenic H5N1 avian influenza A strain (A/Texas/37/2024).

On March 25, 2024, the highly pathogenic avian H5N1 influenza virus was confirmed in a dairy cow in Texas and has continued to spread widely in U.S. dairy cattle, causing a few human cases. There is concern that the H5N1 virus could adapt for human-to-human transmission and potentially result in an influenza pandemic. CC-42344 is a new investigational drug candidate for the treatment of pandemic and seasonal influenza infections. This inhibitor binds to a highly conserved active site of the PB2 protein and inhibits the viral replication process. The Company previously announced the structural and in vitro data of CC-42344 with the purified H5N1 PB2 protein.

The virology study utilized the highly pathogenic H5N1 avian strain (influenza A/Texas/37/2024) and was conducted to test antiviral activity of CC-42344 using Tamiflu® as a reference inhibitor. The data showed that CC-42344 was highly potent against the H5N1 avian influenza virus (EC50, 0.003 µM), approximately 1,000-fold more potent, compared to a refence compound Tamiflu (EC50, 2.69 µM). CC-42344 is currently in development as an oral treatment for pandemic avian and seasonal influenza A infections with initial data showing a favorable safety and tolerability profile.

“We are excited to share these H5N1 results that further validate our structure-based drug discovery platform technology and strengthen our position in developing treatments for influenza infection,” said Sam Lee, PhD, President and co-CEO of Cocrystal Pharma. “These important antiviral data along with the favorable safety profile observed in a Phase 1 study support further clinical evaluation of CC-42344 for pandemic and seasonal flu.”

“We are developing a therapeutic candidate with the potential to address the multibillion-dollar influenza market,” said James Martin, CFO and co-CEO of Cocrystal Pharma. “Influenza is a major global health concern that may become more challenging to treat as highly pathogenic avian viruses emerge and become resistant to approved antivirals. On average, in the U.S. about 8% of the population contracts influenza each season and influenza is responsible for an estimated $11.2 billion in direct and indirect costs annually.”

Avian Influenza
A multistate outbreak of highly pathogenic avian influenza in dairy cows was initially reported in March 2024 and was the first time that avian flu viruses were found in cows. In April 2024 the Centers for Disease Control and Prevention (CDC) confirmed an avian flu infection in a person exposed to dairy cows that were presumed to be infected with the virus. This is believed to be the first instance of likely mammal-to-human spread of this virus. In September 2024 the CDC reported the first human case of avian influenza without a known occupational exposure to sick or infected animals.

The CDC analyzed blood collected from people of all ages in all 10 Department of Health and Human Services regions during the 2022-2023 and 2021-2022 flu seasons. These samples were challenged with the avian flu subtype H5N1 virus to determine whether there was an antibody reaction. Data from this study suggest that there is extremely low to no population immunity to clade 2.3.4.4b A (H5N1) viruses in the U.S. Antibody levels remained low regardless of whether or not participants received a seasonal flu vaccination, meaning that seasonal flu vaccination did not produce antibodies to avian flu H5N1 viruses.

About Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), noroviruses and hepatitis C viruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit www.cocrystalpharma.com.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the potential efficacy of CC-42344 against influenza including the avian influenza A H5N1 virus and the potential market for such product candidate. The words “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events. Some or all of the events anticipated by these forward-looking statements may not occur. Important factors that could cause actual results to differ from those in the forward-looking statements include, but are not limited to, risks relating to our ability to obtain regulatory authority for and proceed with clinical trials including our plans to complete a Phase 2a study for CC-42344, the results of such studies, our and our collaboration partners’ technology and software performing as expected, general risks arising from clinical studies, receipt of regulatory approvals, regulatory changes including based on initiatives and actions taken by the Trump Administration which could, among other things, result in delays in regulatory approvals or limit access to federal funding for our programs, and potential development of effective treatments and/or vaccines by competitors and potential mutations in a virus we are targeting that may result in variants that are resistant to a product candidate we develop. Further information on our risk factors is contained in our filings with the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2024. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

Investor Contact:
Alliance Advisors IR
Jody Cain
310-691-7100
jcain@allianceadvisors.com

# # #

Primary Logo

Source: Cocrystal Pharma, Inc.

Released May 29, 2025

Release – MariMed’s Premium Nature’s Heritage Brand Enters Functional Mushroom Market Launching Plant-Based MycroDose

Posted on by aweinsoff@channelchek.com

Research News and Market Data on MRMD

 Download as PDF

May 29, 2025 7:30am EDT

All-Natural Line of Wellness Products Designed to Support Overall Well-Being Now Available in Massachusetts

NORWOOD, Mass., May 29, 2025 (GLOBE NEWSWIRE) — MariMed Inc. (“MariMed”) (CSE: MRMD) (OTCQX: MRMD), the company behind the award-winning flower and concentrate brand, Nature’s Heritage™, continued to drive innovation with the launch of MycroDose by Nature’s Heritage, a vegan line of all-natural wellness products that combine the power of full-spectrum cannabis with the added benefits of functional mushrooms in a convenient pill form. MycroDose by Nature’s Heritage delivers four targeted, plant-based solutions designed to enhance mental clarity, promote relaxation, improve focus, and support overall well-being in four distinct formulations. They are available now in Massachusetts at MariMed’s own Panacea Wellness stores and other select dispensaries.

The new line was developed to provide new and existing consumers with a unique, balanced, and controlled experience. Each of the four MycroDose by Nature’s Heritage products are uniquely crafted with a specific blend of all natural vegan ingredients to cater to a variety of needs. The complete line-up includes:

  • Chill – Designed for relaxation and stress relief, Chill features THC, CBD, and q, blended with the functional mushrooms Organic Cordyceps and Organic Lion’s Mane, and the root plant, Ashwagandha.
  • G’Night – A formulation aimed at improved sleep and deep relaxation, G’Night combines THC, CBN, CBD with functional mushrooms Organic Reishi and Organic Lion’s Mane, as well as Chamomile and Magnesium.
  • Remedy – A product focused on reducing inflammation while providing a calm state of mind, Remedy features THC, CBD, and CBC, blended with the functional mushroom Oyster, Ginger root, Turmeric, and Piperine.
  • Spark – An energizing blend designed to improve energy, focus, and mental clarity, Spark is formulated with Shiitake mushrooms, Organic Lion’s Mane, Ginseng, THCV, and THC.

“Nature’s Heritage is proud to introduce a groundbreaking new line of products that harnesses the synergy between high-quality cannabis, functional mushrooms, and herbs to deliver a truly elevated experience,” said Tami Kirlis, MariMed Brand Director for Nature’s Heritage. “Our team meticulously researched and developed innovative formulas that enhance well-being, mental clarity, and relaxation in a way that’s truly distinct. Nature’s Heritage prioritizes natural ingredients to enhance health and well-being, and MycroDose by Nature’s Heritage delivers on that mission.”

To learn more about MycroDose by Nature’s Heritage and where to purchase the line in Massachusetts, visit www.naturesheritagecannabis.com.

About MariMed
MariMed Inc. is a leading multi-state cannabis operator, known for developing and managing state-of-the-art cultivation, production, and retail facilities. Our award-winning portfolio of cannabis brands, including Betty’s Eddies™, Bubby’s Baked™, Vibations™, InHouse™, and Nature’s Heritage™, sets us apart as an industry leader. These trusted brands, crafted with quality and innovation, are recognized and loved by consumers across the country. With a commitment to excellence, MariMed continues to drive growth and set new standards in the cannabis industry. For additional information, visit www.marimedinc.com.

Media Contact:
Zach Galasso
DPA Communications
Email: zach@dpacommunications.com
Phone: (978) 604-5423

Company Contact:
Howard Schacter
Chief Communications Officer
Email: hschacter@marimedinc.com
Phone: (781) 277-0007

Primary Logo

Source: MariMed Inc.

Released May 29, 2025

Mortgage Rates Hover Near 7% Pressuring Housing Market and Consumer Confidence

Posted on by slightbourne@noblecapitalmarkets.com
Key Points:
– Mortgage rates edge up — 30-year fixed rates rose to 6.89%, tracking higher Treasury yields.
– Buyer affordability hit — High rates continue to suppress home sales and affordability.
– Applications mixed — Purchase applications rose 3%, while refinance demand fell 7%.

Mortgage rates rose modestly this week, with the average 30-year fixed loan hitting 6.89%, up slightly from 6.86% the week before. The 15-year average also inched higher to 6.03%, reflecting the continued influence of Treasury yields, which have been volatile amid shifting economic signals.

The movement in mortgage rates follows recent fluctuations in the 10-year Treasury yield, a key benchmark for borrowing costs. Investors have been digesting a complex mix of developments, including the U.S. credit rating downgrade, the fiscal implications of proposed tax reforms, and evolving trade policy. While yields dipped slightly in recent days, overall borrowing costs remain elevated.

High mortgage rates continue to act as a headwind for the housing sector. According to newly released data, pending home sales dropped sharply in April, underscoring how rate-sensitive the market remains. Despite a modest weekly increase in home purchase applications, affordability challenges persist, particularly for first-time buyers and middle-income households.

This constrained environment has implications beyond real estate. A sluggish housing market can ripple through related industries—from homebuilding and furniture to construction materials and local services—potentially influencing performance in sectors that rely on consumer confidence and discretionary spending.

Although refinancing activity dropped by 7%, the slight increase in purchase applications signals that some buyers are still moving forward, especially those less sensitive to rate fluctuations or motivated by limited inventory. Nonetheless, sustained high rates may continue to delay broader recovery in housing-related demand.

In this climate, market participants are keeping a close eye on interest rate trends and consumer sentiment data, both of which remain central to shaping the economic outlook. As borrowing costs remain elevated, the pressure on housing and adjacent industries may persist—adding another layer of complexity to growth expectations in the months ahead.